Species |
Human |
Protein Construction |
VEGF R3/FLT4 (Tyr25-Ile776) Accession # P35916-1 |
His |
Avi |
N-term |
|
C-term |
|
Conjugate |
Biotin |
Purity |
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC |
Endotoxin Level |
Less than 1EU per μg by the LAL method. |
Biological Activity |
Immobilized Human VEGF-C, His Tag at 5 μg/ml (100μl/Well) on the plate can bind VEGF R3/FLT4[Biotin], His&Avi, Human (Cat.No.: Z03971) |
Expression System |
HEK293 |
Theoretical Molecular Weight |
87.4 kDa |
Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 115-130 kDa based on Bis-Tris PAGE result. |
Formulation |
Lyophilized from a 0.22 μm filtered solution in PBS, (pH 7.4). |
Reconstitution |
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH2O more than 100 μg/ml. |
Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
![VEGF R3/FLT4[Biotin], His&Avi, Human VEGF R3/FLT4[Biotin], His&Avi, Human](/product/documents/down?doc_name=Z03971 ELISA.jpg&file=scm_files/productFile_notes/2025/03/12/Z03971 ELISA.jpg)
Immobilized Human VEGF-C, His Tag at 5 μg/ml (100 μl/well) on the plate. Dose response curve for VEGF R3/FLT4[Biotin], His & Avi, Human with the EC50 of 23.0 ng/ml determined by ELISA.
![VEGF R3/FLT4[Biotin], His&Avi, Human VEGF R3/FLT4[Biotin], His&Avi, Human](/product/documents/down?doc_name=Z03971 PAGE.png&file=scm_files/productFile_notes/2025/03/12/Z03971 PAGE.png)
VEGF R3/FLT4[Biotin], His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
![VEGF R3/FLT4[Biotin], His&Avi, Human VEGF R3/FLT4[Biotin], His&Avi, Human](/product/documents/down?doc_name=Z03971 HPLC.png&file=scm_files/productFile_notes/2025/03/12/Z03971 HPLC.png)
The purity of VEGF R3/FLT4[Biotin], His & Avi, Human is greater than 95% as determined by SEC-HPLC.
Target Background |
Vascular endothelial growth factor receptor 3 (VEGFR3) is one kind of tyrosine-protein kinase. VEGFR3 acts as a cell-surface receptor for VEGFC and VEGFD. It is a key regulator of lymphatic system development and establishment. VEGFR3 plays important roles in angiogenesis. It is also up-regulated in the endothelium of blood vessels in breast cancer and various other tumors. |
Synonyms |
VEGFR-3; FLT-4; LMPH1A; PCLFLT41; VEGFR3; FLT-41; PCL |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.